Two New Hypertension Tablets Receive Approval

April 2011
Journal of Gerontological Nursing;Apr2011, Vol. 37 Issue 4, p7
Academic Journal
The article reports on approval which the U.S. Food and Drug Administration gave in 2011 for the use of the antihpertensive agents Amturnide and Edarbi. A discussion of research which was conducted on the efficacy and safety of the two drugs, and which the administration evaluated prior to giving approval to the drugs, is presented.


Related Articles

  • Aliskiren: A Review of its Use in the Management of Hypertension. Frampton, James E.; Curran, Monique P. // Drugs;2007, Vol. 67 Issue 12, p1767 

    Aliskiren (Tekturna®) is an orally active, nonpeptidic inhibitor of renin, the enzyme involved in the initial and rate-limiting step of the renin-angiotensin system (RAS). In the US, aliskiren is approved for the treatment of hypertension and may be used alone or in combination with other...

  • BP of 150 adequate for older adults.  // Clinical Advisor;Dec2014, Vol. 17 Issue 12, p20 

    No abstract available.

  • The Relationship Between Casual and Ambulatory Blood Pressure in Essential Hypertension: The Influence of Work, Duration of Hypertension and Antihypertensive Treatment.  // JAMA: Journal of the American Medical Association;9/8/89, Vol. 262 Issue 10, p1317 

    Discusses the abstract of the article 'The Relationship Between Casual and Ambulatory Blood Pressure in Essential Hypertension: The Influence of Work, Duration of Hypertension and Antihypertensive Treatment,' by H. Eiskjaer et al, featured in a 1989 issue of the 'Journal of Internal Medicine.'

  • New survey on antihypertensive medications reveals significant drug tolerability problems. Roller, Kim // Drug Store News;12/13/99, Vol. 21 Issue 20, p54 

    Provides information on a national survey on the use of antihypertensive medications released by the Association of Black Cardiologists. Reason some patients being treated for hypertension may stop taking their medication; Misunderstanding on elevated systolic blood pressure; Extent of the...

  • Differential regulations of blood pressure and perturbed metabolism by total ginsenosides and conventional antihypertensive agents in spontaneously hypertensive rats. Ji-ye AA; Guang-ji WANG; Hai-ping HAO; Qing HUANG; Yi-hong LU; Bei YAN; Wei-bin ZHA; Lin-sheng LIU; An KANG // Acta Pharmacologica Sinica;Aug2010, Vol. 31 Issue 8, p930 

    AbstractAim:To investigate the regulatory effects of total ginsenosides and the conventional antihypertensive agents (captopril, amlodipine, terazosin and hydrochlorothiazide) on the blood pressure and perturbed metabolism in spontaneously hypertensive rats (SHRs) and to analyze the cause-effect...

  • The New Hypertension Guidelines From JNC 7: Is the Devil in the Details? Textor, Stephen C.; Schwartz, Gary L.; Frye, Robert L. // Mayo Clinic Proceedings;Sep2003, Vol. 78 Issue 9, p1078 

    Editorial. Discusses the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure's guidelines for the management of hypertension. Blood pressure classification for adults; Blood pressure treatment goals; Antihypertensive therapy; Combination drug therapy.

  • Apparent and true resistant hypertension: definition, prevalence and outcomes. Judd, E; Calhoun, D A // Journal of Human Hypertension;Aug2014, Vol. 28 Issue 8, p463 

    Resistant hypertension, defined as blood pressure (BP) remaining above goal despite the use of ⩾3 antihypertensive medications at maximally tolerated doses (one ideally being a diuretic) or BP that requires ⩾4 agents to achieve control, has received more attention with increased...

  • Effects of renal sympathetic denervation on 24-hour blood pressure variability. Zuern, Christine S.; Rizas, Konstantinos D.; Eick, Christian; Stoleriu, Cosmina; Bunk, Lena; Barthel, Petra; Balletshofer, Bernd; Gawaz, Meinrad; Bauer, Axel // Frontiers in Physiology;May2012, Vol. 3, p1 

    Background: In patients with arterial hypertension, increased blood pressure (BP) variability contributes to end organ damage independently from mean levels of arterial BP. Increased BP variability has been linked to alterations in autonomic function including sympathetic overdrive. We...

  • Treatment of Acute Severe Hypertension: Current and Newer Agents. Varon, Joseph // Drugs;2008, Vol. 68 Issue 3, p283 

    Approximately 72 million people in the US experience hypertension. Worldwide, hypertension may affect as many as 1 billion people and be responsible for ≈7.1 million deaths per year. It is estimated that ≈1% of patients with hypertension will, at some point, develop...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics